Avexitide clinical trials
Also written Exendin (9-39).
Includes 1 study of Avexitide acetate.
How each study uses avexitide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the avexitide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 34
Mayo Clinic (7) · Diva De Leon (4) · Adrian Vella (3) · Tracey McLaughlin (3) · The University of Texas Health Science Center at San Antonio (3) · University Hospital, Gentofte, Copenhagen (2) · Ludwig-Maximilians - University of Munich (2) · Amylyx Pharmaceuticals Inc. (1)
Often tested with
Tested in the same studies.
Atropine (3) · Glucagon-Like Peptide 1 (2) · Liraglutide (1) · Acarbose (1) · Metformin (1) · Pegvisomant (1) · Omega-N-Methylarginine (1) · Sitagliptin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test avexitide.
- Oct 2027The Role of Islet GLP-1 in the Pathogenesis of PrediabetesPhase 2 · Mayo Clinic
Studies
Open first, then newest update. How each study uses avexitide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 36
- Islet Function in Gestational DiabetesRecruitingPhase 1Mayo ClinicNCT07806695Written as Exendin 9-39
- The Effect of rs7903146 Genotype on Islet GLP-1 Production in HumansNot yet recruitingPhase 2Mayo ClinicNCT06972407Written as Exendin 9-39
- The Role of Islet GLP-1 in the Pathogenesis of PrediabetesRecruitingPhase 2Mayo ClinicNCT06967558Written as Exendin 9-39
- The Effects of Bariatric Surgeries on Glucose MetabolismRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT02823665Written as Exendin-(9-39)
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT00992901Written as Exendin-(9-39)
- Glucagon-like Peptide 1, Glucose Metabolism and Gastric BypassRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT01803451Written as exendin-(9-39)
- A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in NondiabeticsCompletedPhase 3Adrian VellaNCT04466566Written as Exendin-9,39
- Avexitide for Treatment of Post-Bariatric HypoglycemiaActive, not recruitingPhase 3Amylyx Pharmaceuticals Inc.NCT06747468Written as Avexitide
- The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 DiabetesCompletedNot applicableAsger Lund, MDNCT07373236Written as exendin(9-39)amide
- Regulation of Insulin Secretion by the GLP-1 ReceptorTerminatedPhase 4VA Office of Research and DevelopmentNCT02844907Written as Exendin (9-39)
- Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric HypoglycemiaCompletedPhase 1Tracey McLaughlinNCT02996812Written as Exendin (9-39)
- Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric SurgeryTerminatedPhase 1Tracey McLaughlinNCT02550145Written as Exendin (9-39)
- Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 DiabetesCompletedPhase 3Adrian VellaNCT04466618Written as Exendin-9,39
- A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin SecretionCompletedPhase 3Adrian VellaNCT04459338Written as Exendin-9,39
- Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic HypoglycemiaCompletedPhase 2Dr. Tracey McLaughlin, MDNCT04652479Written as Avexitide
- Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric HypoglycemiaCompletedPhase 2Eiger BioPharmaceuticalsNCT03373435Written as exendin 9-39
- The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 DiabetesCompletedPhase 2Mayo ClinicNCT02762708Written as Exendin-9,39
- Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric HypoglycemiaCompletedPhase 2Tracey McLaughlinNCT02771574Written as Lyo avexitide
- Effect of Exendin (9-39) on Glucose Requirements to Maintain EuglycemiaTerminatedPhase 1/2Diva De LeonNCT00835328Written as Exendin (9-39)
- Exendin-9,39 and Satiety After Bariatric SurgeryCompletedNot applicableMayo ClinicNCT02779075Written as Exendin-9,39
See all 36 studies that test avexitide →
Given beside what is tested · 2 — avexitide is usual care or a partner of the new treatment
- Cardiovascular Effects of GLP-1 Receptor ActivationCompletedPhase 4Vanderbilt University Medical CenterNCT03101930Written as Exendin (9-39)
- The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and PrediabetesCompletedPhase 4Carl T. Hayden VA Medical CenterNCT01181986Written as Exendin-9
As the comparator · 1 — what is tested is compared with avexitide
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call avexitide · ClinicalTrials.gg INT003753
- MeSH (NLM) C083773exendin (9-39)Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5313W10MYTAVEXITIDEConfirmed FDA, NLM
- NCI Thesaurus C133230AvexitideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C083773 | exendin (9-39) | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5313W10MYT | AVEXITIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C133230 | Avexitide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.